Diabetes 68(1):131-140, 2019
- Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD)
- Gubra once more awarded EY Entrepreneur Of The Year, Region Zealand.
- Gubra strengthens Board of Directors with two international appointments
- Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments
- Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform